3SBIO1530.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, 3SBIO (1530.HK) trades at a P/E of 3.95x, P/B of 1.16x, P/S of 1.82x, and a dividend yield of 1.72%.
Longitudinal percentile comparison: P/E sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/B sits at the 23rd percentile over the trailing 10Y window (vs. 42nd percentile over 3Y); P/S sits at the 15th percentile over the trailing 10Y window (vs. 36th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 8th percentile within its industry and the 12th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 2.79%, ranking at the 80th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 22.6 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 1.72% comes from cash dividends, with an implied ~1.07% from buybacks — a fairly balanced mix of both channels. 3SBIO operates in the Biomedical II sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 1530 · SEHK: 1530 · 1530
Want the full picture on whether 3SBIO (1530.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 3.95 | ||||||
| P/B (MRQ) | 1.16 | ||||||
| P/S (TTM) | 1.82 | ||||||
| Dividend Yield | 1.72% | ||||||
| Buyback + Div Yield | 2.79% |